The global chronic kidney disease (CKD) drugs market is witnessing steady growth as the prevalence of kidney disorders continues to rise worldwide and pharmaceutical companies expand their portfolios of renal therapies. According to the latest industry analysis, the global CKD drugs market was valued at US$ 14.8 billion in 2023 and is projected to reach US$ 23.8 billion by the end of 2034, expanding at a CAGR of 4.2% from 2024 to 2034.

The market is primarily driven by the increasing incidence of chronic kidney disease associated with diabetes, hypertension, aging populations, and other chronic conditions. At the same time, advances in cardiorenal medicine and the approval of new therapies are creating additional opportunities for drug manufacturers.

Commonly used CKD medicines include ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents, and diuretics. Newer therapeutic classes, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors, are also expanding the treatment landscape by helping reduce the risk of kidney disease progression and associated cardiovascular complications in appropriate patient populations.

Rising Incidence of Chronic Kidney Disease Drives Market Growth

The growing global burden of chronic kidney disease is one of the most important factors supporting market expansion.

CKD is characterized by a gradual and often progressive loss of kidney function. Damaged kidneys become less capable of filtering waste and excess fluids from the blood, potentially leading to complications affecting cardiovascular, metabolic, and overall health.

Diabetes and hypertension are among the major conditions associated with CKD. As the prevalence of these chronic diseases increases, the population requiring kidney disease management and pharmacological treatment is also expanding.

According to the U.S. Centers for Disease Control and Prevention, more than one in seven U.S. adults are estimated to have CKD. This substantial patient population creates sustained demand for medicines aimed at controlling blood pressure, managing complications, slowing disease progression, and reducing associated health risks.

The increasing focus on early diagnosis is also supporting pharmaceutical demand. Healthcare providers are increasingly emphasizing regular monitoring of kidney function among high-risk populations, particularly individuals with diabetes and hypertension.

Early intervention can help healthcare professionals manage underlying conditions and potentially delay progression to advanced kidney disease. Consequently, greater awareness of kidney health and improved screening practices are expected to contribute to long-term CKD drugs market development.

Diabetes and Hypertension Strengthen Demand for CKD Therapies

The close relationship between CKD, diabetes, and hypertension continues to influence pharmaceutical demand.

Diabetic kidney disease is a major complication associated with long-term diabetes. Persistent high blood glucose levels can damage the kidney's filtering structures and gradually impair renal function.

Similarly, uncontrolled hypertension can damage blood vessels within the kidneys, reducing their ability to filter blood effectively. CKD can also worsen hypertension, creating a cycle that increases the risk of disease progression and cardiovascular complications.

This connection has encouraged pharmaceutical companies to develop therapies that address multiple aspects of cardiorenal metabolic health.

SGLT2 inhibitors have gained considerable attention because of their demonstrated benefits in appropriate patients with CKD, particularly regarding slowing kidney disease progression and reducing certain cardiovascular risks.

Research into additional therapies that target metabolic and renal pathways is also expanding the treatment pipeline. Continued investment in clinical research is expected to generate new therapeutic options and support market growth throughout the forecast period.

Approval and Launch of New Drugs Accelerate Market Expansion

The approval of innovative medicines is another major factor contributing to the growth of the global CKD drugs market.

Regulatory approvals expand the number of treatment options available to physicians and patients while creating new commercial opportunities for pharmaceutical companies. The growing clinical evidence supporting therapies that protect kidney function has particularly strengthened the CKD treatment landscape.

In September 2023, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death, and hospitalization in certain adults with CKD at risk of progression.

The approval was supported by findings from the EMPA-KIDNEY clinical trial, which evaluated empagliflozin across a broad population of adults with CKD, including patients with and without type 2 diabetes.

Such regulatory developments demonstrate the increasing focus on therapies that can address both renal and cardiovascular outcomes. As clinical evidence continues to establish the benefits of newer drug classes, pharmaceutical companies are likely to increase investments in renal drug development.

SGLT2 Inhibitors Transform the CKD Treatment Landscape

SGLT2 inhibitors represent one of the most significant developments in the modern CKD treatment landscape.

Medicines in this class include canagliflozin, dapagliflozin, and empagliflozin. Originally developed primarily for glucose management in people with type 2 diabetes, these therapies have demonstrated broader cardiorenal benefits in appropriate patient populations.

Their ability to reduce the risk of kidney disease progression has encouraged wider clinical adoption and expanded their role in chronic disease management.

The growing integration of diabetes, cardiovascular, and renal care is also encouraging pharmaceutical companies to pursue therapies that provide benefits across multiple disease areas.

As healthcare systems increasingly prioritize prevention of kidney failure and reduction of costly complications, demand for evidence-based therapies that can delay disease progression is expected to remain strong.

Research and Development Creates New Market Opportunities

Pharmaceutical companies are significantly increasing investments in renal research and development to address unmet medical needs.

CKD encompasses multiple disease pathways and underlying causes, creating opportunities for therapies designed for specific patient populations. Researchers are exploring mechanisms associated with inflammation, fibrosis, metabolic dysfunction, immune system activity, and other processes involved in kidney disease progression.

The development of precision approaches may eventually allow treatment decisions to be more closely aligned with individual patient characteristics and disease mechanisms.

Biomarker research is also expected to improve patient identification and treatment monitoring. Better diagnostic and monitoring tools can help clinicians identify disease progression earlier and determine whether patients are responding adequately to therapy.

Strategic partnerships and licensing agreements are another important feature of the competitive landscape. Pharmaceutical companies are collaborating with biotechnology firms to gain access to promising investigational therapies and strengthen their renal pipelines.

North America Leads the Global CKD Drugs Market

North America held the largest share of the global chronic kidney disease drugs market in 2023 and is expected to maintain its leading position during the forecast period.

The region benefits from a large population affected by CKD, well-developed healthcare infrastructure, extensive pharmaceutical research capabilities, and relatively high access to advanced medicines.

The United States is particularly important to regional market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 37 million people in the U.S. have kidney disease, representing more than one in seven adults.

The presence of major pharmaceutical companies and strong investment in clinical research further supports market development. Regulatory approvals for innovative renal therapies also enable new products to enter the market and expand treatment options.

Europe represents another significant market, supported by established healthcare systems and growing attention toward chronic disease management.

Asia Pacific is expected to offer considerable long-term growth opportunities as diabetes, hypertension, and other risk factors for CKD become increasingly prevalent. Improvements in healthcare infrastructure, diagnostic capabilities, and access to pharmaceutical treatments are likely to support regional expansion.

Hospitals and Specialty Clinics Remain Key End Users

Hospitals and specialty clinics represent important end-user segments for CKD drugs.

Hospitals play a central role in managing patients with advanced kidney disease, acute complications, and multiple comorbidities. They also serve as major centers for diagnosis, treatment initiation, and management of complex renal conditions.

Specialty clinics provide ongoing disease management and monitoring for patients with chronic kidney disorders. As CKD increasingly becomes part of integrated chronic disease management programs, specialty healthcare providers are expected to remain important purchasers and administrators of renal therapies.

The growing emphasis on outpatient care and long-term disease management may also influence how CKD medicines are prescribed and distributed.

Competitive Landscape

The global CKD drugs market is characterized by competition among major pharmaceutical companies developing therapies for kidney disease, associated complications, and cardiorenal metabolic conditions.

Prominent companies include F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co., Ltd., AbbVie Inc., Akebia Therapeutics, Inc., AstraZeneca, Amgen Inc., and Teva Pharmaceutical Industries Ltd.

Companies are focusing on expanding renal portfolios, advancing clinical pipelines, strengthening drug development capabilities, and establishing strategic partnerships.

The market is also witnessing greater convergence between renal, cardiovascular, and metabolic drug development. This approach allows companies to develop therapies that address multiple interconnected conditions while potentially improving patient outcomes.

Strategic licensing and collaboration agreements are expected to remain important as pharmaceutical companies seek access to innovative molecules and specialized biotechnology platforms.

Recent Industry Developments

Recent regulatory and strategic developments demonstrate the rapid evolution of the CKD treatment landscape.

In July 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the European Commission approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease. The decision expanded the medicine's role beyond its established applications and reinforced the importance of SGLT2 inhibition in renal care.

In July 2022, F. Hoffmann-La Roche Ltd. entered into a partnership with Ionis Pharmaceuticals for licensing rights to IONIS-FB-LRx, an investigational therapy targeting complement factor B for immunoglobulin A nephropathy. The agreement strengthened Roche's focus on rare kidney diseases and potential therapies for conditions that can progress to CKD and kidney failure.

In March 2024, Novo Nordisk announced results from a trial indicating that semaglutide reduced the risk of kidney disease progression by 24% in people with type 2 diabetes and CKD. Such findings highlight the growing convergence between metabolic and renal disease treatment.

Future Outlook

The global chronic kidney disease drugs market is projected to increase from US$ 14.8 billion in 2023 to US$ 23.8 billion by 2034, registering a CAGR of 4.2% from 2024 to 2034.

The market's long-term growth will be supported by the rising prevalence of CKD and its major risk factors, particularly diabetes and hypertension. Increased awareness of kidney health and greater adoption of screening and early disease-management programs are also expected to expand the treated patient population.

At the same time, the development and approval of innovative medicines will remain a central growth driver. SGLT2 inhibitors have already reshaped the treatment landscape, while ongoing research into metabolic, inflammatory, immune, and fibrotic pathways is creating opportunities for new therapies.

North America is expected to remain the leading regional market, while Asia Pacific offers significant expansion potential as healthcare access and chronic disease management improve.

Overall, the combination of rising disease prevalence, increasing emphasis on delaying kidney disease progression, advances in cardiorenal medicine, and continued pharmaceutical innovation is expected to sustain steady growth in the global CKD drugs industry through 2034.